Immunic (IMUX) Competitors $0.89 0.00 (-0.43%) Closing price 04:00 PM EasternExtended Trading$0.91 +0.01 (+1.50%) As of 06:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMUX vs. AURA, REPL, DSGN, IMAB, BNTC, ALTS, DMAC, CAPR, ALT, and ACIUShould you be buying Immunic stock or one of its competitors? The main competitors of Immunic include Aura Biosciences (AURA), Replimune Group (REPL), Design Therapeutics (DSGN), I-Mab (IMAB), Benitec Biopharma (BNTC), ALT5 Sigma (ALTS), DiaMedica Therapeutics (DMAC), Capricor Therapeutics (CAPR), Altimmune (ALT), and AC Immune (ACIU). These companies are all part of the "pharmaceutical products" industry. Immunic vs. Its Competitors Aura Biosciences Replimune Group Design Therapeutics I-Mab Benitec Biopharma ALT5 Sigma DiaMedica Therapeutics Capricor Therapeutics Altimmune AC Immune Aura Biosciences (NASDAQ:AURA) and Immunic (NASDAQ:IMUX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment. Which has more risk and volatility, AURA or IMUX? Aura Biosciences has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500. Comparatively, Immunic has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500. Which has stronger valuation & earnings, AURA or IMUX? Aura Biosciences is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAura BiosciencesN/AN/A-$86.92M-$1.96-3.13ImmunicN/AN/A-$100.51M-$0.94-0.95 Is AURA or IMUX more profitable? Aura Biosciences' return on equity of -64.44% beat Immunic's return on equity.Company Net Margins Return on Equity Return on Assets Aura BiosciencesN/A -64.44% -54.24% Immunic N/A -461.46%-217.16% Do institutionals and insiders have more ownership in AURA or IMUX? 96.8% of Aura Biosciences shares are held by institutional investors. Comparatively, 51.8% of Immunic shares are held by institutional investors. 6.3% of Aura Biosciences shares are held by insiders. Comparatively, 4.6% of Immunic shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Do analysts recommend AURA or IMUX? Aura Biosciences presently has a consensus price target of $22.00, suggesting a potential upside of 258.89%. Immunic has a consensus price target of $9.50, suggesting a potential upside of 961.93%. Given Immunic's higher possible upside, analysts plainly believe Immunic is more favorable than Aura Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aura Biosciences 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78Immunic 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Does the media favor AURA or IMUX? In the previous week, Aura Biosciences had 1 more articles in the media than Immunic. MarketBeat recorded 5 mentions for Aura Biosciences and 4 mentions for Immunic. Aura Biosciences' average media sentiment score of 0.81 beat Immunic's score of 0.62 indicating that Aura Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aura Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunic 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAura Biosciences beats Immunic on 10 of the 14 factors compared between the two stocks. Get Immunic News Delivered to You Automatically Sign up to receive the latest news and ratings for IMUX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMUX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMUX vs. The Competition Export to ExcelMetricImmunicMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$88.25M$3.33B$6.04B$10.44BDividend YieldN/A2.31%5.73%4.79%P/E Ratio-0.9522.2285.3127.07Price / SalesN/A439.84588.57190.17Price / CashN/A44.9825.7330.17Price / Book4.4710.3812.666.69Net Income-$100.51M-$52.31M$3.31B$276.03M7 Day Performance-4.83%0.59%-0.44%-1.13%1 Month Performance12.63%13.90%8.70%6.49%1 Year Performance-36.10%28.95%76.70%34.41% Immunic Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMUXImmunic2.2168 of 5 stars$0.89-0.4%$9.50+961.9%-35.8%$88.25MN/A-0.9570AURAAura Biosciences1.9682 of 5 stars$5.92-2.2%$22.00+271.9%-34.8%$367.50MN/A-3.0250Positive NewsREPLReplimune Group4.6747 of 5 stars$4.69-0.8%$6.50+38.5%-60.5%$365.71MN/A-1.45210DSGNDesign Therapeutics0.1983 of 5 stars$6.37+4.3%N/A+35.0%$362.77MN/A-5.6940IMABI-Mab2.736 of 5 stars$4.40+1.7%$7.33+66.9%+275.6%$361.43M$3.89M0.00380Analyst UpgradeGap UpBNTCBenitec Biopharma1.9784 of 5 stars$13.69-1.1%$24.80+81.2%+37.4%$359.49M$80K-9.3220ALTSALT5 Sigma0.4926 of 5 stars$2.94+2.3%N/A+45.3%$358.63M$12.53M0.00170Positive NewsGap DownDMACDiaMedica Therapeutics1.9179 of 5 stars$6.93-1.9%$12.33+77.9%+56.2%$357.64MN/A-10.0320CAPRCapricor Therapeutics1.9373 of 5 stars$7.83+6.4%$22.25+184.0%-60.1%$357.53M$22.27M-4.77101ALTAltimmune2.9759 of 5 stars$4.03+3.2%$17.40+331.3%-37.8%$355.25M$20K-3.4150Analyst ForecastACIUAC Immune1.8992 of 5 stars$3.55-11.0%$10.00+181.7%+6.9%$354.45M$31.02M-6.09140Positive NewsHigh Trading Volume Related Companies and Tools Related Companies Aura Biosciences Alternatives Replimune Group Alternatives Design Therapeutics Alternatives I-Mab Alternatives Benitec Biopharma Alternatives ALT5 Sigma Alternatives DiaMedica Therapeutics Alternatives Capricor Therapeutics Alternatives Altimmune Alternatives AC Immune Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMUX) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
